Comments
Venus Remedies today received additional patent approval from the United States Patent and Trademark Office (USPTO) for its product ‘Vancoplus’, used for treating bacterial infections.
“Venus Remedies already has product patent for Vancoplus from USPTO. This additional patent with broader coverage for use and method of treatment will be beneficial for the company,” Venus Remedies said in a filing to the BSE.
The patent is valid till 2032 and the company has already initiated pre-investigational new drug meeting with the US health regulator, it added.
Vancoplus is a highly effective remedy to control Methicillin-resistant Staphylococcus aureus (MRSA), VRSA (Vancomycin Resistance Staphylococcus aureus) and other bacterial infections.
Global anti-bacterial market is slated to reach around $64 billion by 2018, Venus Remedies said.
Shares of Venus Remedies were trading at Rs 302.80 per scrip in the afternoon trade on the BSE, up 0.26 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.